1 Personalized CZA-ATM dosing against an XDR *E. coli* in liver transplant

2 patients; the application of the *in vitro* hollow fibre infection model

3 (HFIM)

- Zahra Sadouki ^{1, 2},[®] Emmanuel Q. Wey ^{2, 3},[®] Sateesh lype⁴, David Nasralla⁴, Jonathan Potts ⁵,
- 5 Mike Spiro ^{6,7} Alan Williams⁸ Timothy D. McHugh ², Frank Kloprogge¹
- 6 1 Institute for Global Health, University College London, UK
- 7 2 Centre of Clinical Microbiology, University College London, UK
- 8 3 Department of Infection, Royal Free London NHS Trust, UK
- 9 4 Department of HPB and Liver Transplant Surgery Royal Free Hospital
- 10 5 Department of Hepatology, Sheila Sherlock Liver Unit, Royal Free London
- 11 6 Department of Surgical biotechnology, UCL
- 12 7 Department of Intensive care medicine Royal Free London
- 13 8 Department of Infection Sciences, Health Services Laboratories, London, UK,
- 14
- 15 ^a Both authors contributed equally
- 16 **Corresponding author:** Dr Emmanuel Wey, Department of Infection, Consultant and Honorary Associate
- 17 Professor in Infection, Royal Free London NHS Trust, Centre for Clinical Microbiology, Division of
- 18 Infection & Immunity, University College London
- 19 <u>emmanuel.wey@nhs.net</u>
- 20 Keywords: XDR Escherichia coli, Ceftazidime-Avibactam, Aztreonam, personalised medicine, hollow fibre
- 21 infection model
- 22 Electronic word count: 2193 (excluding reference list)
- 23 Number of figures: One main figure, one supplementary figure
- 24 **Number of tables**: Three supplementary tables
- 25 **Conflict of interest statement:** No conflicts of interest.
- 26 **Financial support statement:** This work was conducted as part of Z.S.'s PhD studentship that was
- 27 partially funded by an educational grant from Shionogi B.V. and by University College London. FK has
- 28 been recipient of a UKRI Medical Research Council Skills Development Fellowship MR/P014534/1, and a
- 29 Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant number
- 30 220587/Z/20/Z).
- 31 Authors contribution statement: All authors contributed to the inception and planning of the work. ZS
- 32 and EW[®] wrote the manuscript and contributed equally, and all authors edited.

33 Abstract

Background & aims: An extensively-drug resistant (XDR) NDM and OXA-48 producing *E. coli* contributing
to repeat episodes of biliary sepsis was isolated from the blood stream of a 45-55 year-old male with a
background of IgG4 related sclerosing cholangitis. The patient was awaiting orthotopic liver transplant
(OLT). There is no standardized antibiotic prophylaxis regimen however in line with the Infectious
Diseases Society of America (IDSA) guidance an antibiotic prophylactic regimen of CeftazidimeAvibactam (CZA) 2.5g TDS with Aztreonam (ATM) 2g TDS IV was proposed.

40 **Methods**: To inform the individualised pharmacodynamic outcome likelihood prior to prophylaxis dosing 41 the hollow fibre infection model (HFIM) was applied to simulate the *in vivo* antibiotic exposures of the 42 CZA-ATM regimen. The HFIM was inoculated with ~10 x 10⁵ bacterial CFU/mL of the XDR *E. coli* strain 43 and CFUs/mL were measured for a total of 120 hours to determine the *in vitro* PK/PD killing dynamics.

Results: A 4-log reduction in CFU/mL in the first ten hours of the regimen exposure was observed however the killing dynamics were slow and six eight-hourly infusions were required to reduce bacterial cells to below the limit of quantification. Thus, the HFIM supported the use of the regimen for infection clearance however highlighted the need for several infusions. Standard local practise is to administer prophylaxis antibiotics at induction of OLT however the HFIM provided data to rationalise earlier dosing therefore the patient was dosed at 24 hours prior to their OLT induction. The patient was subsequently discharged 8 days after surgery.

51 **Conclusions:** The HFIM provides a dynamic culture solution for informing individualised medicine by 52 testing antibiotic combinations and exposures against the bacterial isolates cultured from the patient's 53 infection.

54 Introduction

55 Antibiotic prophylaxis in the perioperative period is the standard of care and routinely prescribed during 56 surgical procedures including solid organ transplantation (SOT). Although evidence suggests an overall 57 benefit in reducing postoperative infections the standard of care regimen and duration vary between transplant centres¹⁻³. Here we present the application of the Hollow Fibre Infection Model (HFIM) to 58 59 inform perioperative personalised antimicrobial dosing in a complex clinical setting. It is anticipated that 60 antimicrobial combination therapy will require case-by-case based selection, accounting for individual risk factors and local patterns of resistance, given the rising incidence of multi drug resistant infections 61 62 in solid organ transplant donors and recipients. Systematic reviews and meta-regression analysis has 63 indicated that a there is statistically significant risk associated with gastrointestinal-tract colonisation of carbapenem resistant enterobacterales (CRE) and subsequent infection with CRE⁴. 64 Informing personalised dosing requires in vitro testing beyond MIC reporting which for XDR and PDR infections 65 only serves to highlight the limited options of antimicrobials⁵. In these contexts, HFIM provides an *in* 66 vitro tool which can inform perioperative dosing. The semi permeable hollow fibres retain the bacteria 67 68 in the extra capillary space (ECS) whilst allowing for flow of nutrients and drugs. Therefore, the bacteria 69 isolated from the patient can be challenged against dynamic in vivo mimicking antimicrobial exposures to investigate bacterial PD⁶. 70

71 Materials/Patients and methods

72 Information on clinical findings and diagnostic assessment

73 An inpatient 45-55 year-old male at University College London Hospitals NHS Foundation Trust (UCLH), 74 also under the care of Hepatology and Hepatobiliary surgery teams at Royal Free London NHS 75 Foundation Trust (RFL), previously diagnosed with IgG related sclerosing cholangitis4 presented with 76 recurrent biliary sepsis over a three-month period. Source control of the infections was not achieved by 77 empirical antibiotic treatment due to the presence of three metallic stents in his biliary tree and an 78 internalised percutaneous biliary drain. Blood culture samples and testing of the perihepatic collection 79 fluid confirmed several MDR NDM, and OXA-48 positive gram-negative bacterial strains (Supplementary 80 Table 3) with a combined resistance across nine major antibiotic classes. Further complicating the patient's clinical management was the damage to the liver and loss of synthetic function therefore at 81 82 the time the patient was placed on the NHS waiting list for orthotopic liver transplantation (OLT). The 83 Infectious Diseases Society of America (IDSA) guidance on the treatment of antimicrobial-resistant gram-

negative infections particularly MBL-producing CRE (e.g., NDM, IMP, VIM) suggests intravenous three
times daily dosing of 2.5g Ceftazidime-Avibactam (CZA) in addition to 2g aztreonam (ATM)⁷. In addition,
several clinical infectious disease publications report efficacy of CZA plus ATM in patients with BSIs ⁸⁻¹⁰.
Further antibiotic susceptibility testing (AST) revealed CZA-ATM synergy where ATM activity was
restored when in combination with AVI (Supplementary Table 1). Therefore, the HFIM was employed as
a proof of concept to simulate the *in vivo* dynamic concentrations of the proposed treatment of a threeway antibiotic dosing regimen to be administered to a clinically complex patient.

91 Laboratory consumables and experimental setup

92 The laboratory control strain (ATCC 25922[®]) and the clinical isolate (XDR *E. coli*) were prepared 93 identically. Each were cultured at 37°C in ambient air on nutrient agar and cryopreserved in Microbank[™] 94 beads at -80°C. MICs were determined following CLSI guidelines for microbroth dilution¹¹. A mid-log 95 phase inoculum for each isolate was prepared for the HFIM by refreshing a fresh overnight culture 96 incubated in a shaking incubator at 200 rpm and 37°C in cation adjusted Mueller Hinton broth (CAMHB; 97 Sigma, UK). A 1:50 dilution from this culture was performed to inoculate the HFIM ECS, achieving a final 98 bacterial load of 10⁵ CFU/mL in the ECS.

99 The R-Shiny web application promoted by The International Society of Anti-Infective Pharmacology 100 (ISAP) and ESCMID PK/PD of anti-infectives study group (EPASG) was used to define experimental setup 101 parameters¹². The following C_{max} concentrations were mimicked; CAZ 80 µg/L, AVI 14 µg/L, ATM 120 102 µg/L. A T₁₂ of 2.48 hours was simulated in the HFIM. Antibiotic powders were dissolved in solvents 103 recommended by the manufacturers (CAZ; Sigma, AVI; MCE and ATM; TOKU-E).

104 CAMHB (Sigma; UK) was broth media used in the HFIM system. The hollow fibre cartridge was sourced 105 from FibreCell systems (High flux PS, C2011). The FibreCell duet pump was set at 100 mL/min to allow 106 the cartridge and central reservoir to reach equilibrium. A peristaltic pump (Minipuls evolution[®], Gilson) 107 was set at 0.699 mL/min to mimic T_½ of 2.48. The syringe driver pumps (AL-1000, WPI) were 108 programmed to automatically dose 2 mL infusions every 8 hours over 2 hours and 1 hour respectively 109 for CZA and ATM, administration was concurrent and direct into the central reservoir. Dosing timepoints 100 were at 0, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104 and 112.

The cartridge ECS was sampled on Mueller Hinton agar (MHA) (VWR; UK) to quantify CFUs as well as on colombia blood agar (VWR; UK) to confirm the absence of contamination. The experiment with the laboratory control strain (ATCC 25922[®]) and the clinical isolate (XDR *E. coli*) were both performed in

biological duplicate and all bacterial CFU/mL measurements were performed in technical duplicates at
timepoints 0, 2, 4, 6, 8, 10 to capture the initial killing dynamics then again, every 24 hours for five days
to capture sustained killing or re-growth.

117 **Results**

118 MICs demonstrated synergy between ATM-AVI against the XDR *E. coli* isolated from the patients' blood 119 stream. MICs were as follows CAZ; >80, AVI; >14, ATM; >120, CZA; >32/4, ATM-AVI; 2/4 and CZA-ATM; 120 2.5/0.44/3.8. Although CLSI and EUCAST are yet to establish breakpoints for the ATM-AVI combination, 121 this MIC and synergy data seen fell within range of previous *in vitro* studies reporting MICs between 122 $\leq 0.03/4$ and $8/4 \mu g/mL$, most typically $\leq 2/4 \mu g/mL$ for MBL-producing Enterobacterales^{13,14}.

123 The XDR E. coli challenged with CZA-ATM combination therapy infusions produced a steady rate of 124 killing for the first 10 hours with a 4-log reduction in bacterial CFU/mL however six eight-hourly infusions 125 were required to reduce bacterial cells to below the limit of quantification (Figure 1). Therefore, multiple 126 infusions were required to achieve bacterial source control. The HFIM data demonstrated the proposed 127 combination therapy was only effective at clearing the XDR E. coli after two days of administration of 128 eight hourly infusions. Thus, this suggests longer extended infusions or earlier administration of 129 prophylaxis would be necessary for this patient as towards the end of the infusion the simulated 130 concentration of both ATM and CAZ drop below their respective MICs.

131 In general clamping of the inferior vena cava occurs at two to three hours after induction followed by 132 anhepatic period from three to four hours post induction of the OLT during which the mobilisation and 133 explantation of the native Liver takes place. It would be at this point when and mobilisation and removal 134 of the primary prosthetic sources of XDR biofilm would take place. Surgical implantation of the new 135 deceased donor graft would therefore theoretically coincide with the MIC nadir and potential 136 bacteraemia resulting from explantation of the native liver and if the first dose were given at induction it 137 would also coincide a CFU/mL load above the LOD. This informed the patients antibiotic prophylaxis, 138 and Ceftazidime avibactam 2.5g lv and Aztreonam 2g IV were first dosed at 12 hours prior to the 139 anhepatic phase of their OLT induction thus different to the standard local practise of administering 140 prophylaxis antibiotics at induction of OLT 8-hoturly for a total period of 48 hours. The patient received a DCD graft with side-to-side piggyback anastomosis and portal vein end-to-end anastomosis and Roux-141 142 en-Y Hepaticojejunostomy with removal of a previously internalised percutaneous biliary drain.

143 The patient was discharged 8 days after surgery and had no reoccurrence of XDR *E. coli* infection 144 reported in the year after follow up. Incidentally, the patient has also remained CRE negative on 145 screening post OLT.

146 **Conclusions**

147 Several attempts have been made to develop in vitro laboratory susceptibility testing methods for the combination of CZA with ATM against XDR GNB¹⁵⁻¹⁷. However, these methods test static antibiotic 148 149 concentrations. Here we challenged a patient XDR BSI isolate against dynamic in vivo simulated 150 concentrations of the CZA-ATM antibiotic combination. The HFIM data demonstrated the CZA-ATM 151 antibiotic regimen was effective at clearing the bacterial cells below the limit of detection in the hollow 152 fibre ECS however multiple infusions were required. The Royal Free London Trust standard of care is to 153 administer prophylactic antibiotics for orthotopic liver transplant (OLT) at induction³. However, the slow 154 killing dynamics observed in the HFIM provided in vitro evidence to support prophylactic administration 155 prior to OLT as well as an extended prophylactic duration of 48-hours. Therefore, the patient awaiting a 156 liver transplant was dosed 12 hours earlier than standard local practice. The patient was subsequently 157 discharged 8 days after OLT. The unpredictability relating to the timing and lead times associated with 158 deceased donor grafts offers complicates the practicality of commencing antibiotic prophylaxis in this 159 patient cohort far in advance of 12 hours. This is compounded by the requirement to administer both 160 ceftazidime-avibactam and aztreonam concomitantly.

161 The increased application of alternative synergistic combinations of antibiotic agents necessitates 162 improved methodologies and approaches of in vitro evaluation of combination regimens. We 163 demonstrate extended prophylaxis periods are superior for a chronically infected patient where source 164 control has not been achieved with conventional antibiotic treatment and alternative combination 165 regimens are used. The need of standardized methods to support personalised medicine will be 166 increased as the antibiotic resistance era heightens. The HFIM provides a solution to testing different 167 antibiotic regimens against the exact bacterial isolate cultured from the patient. Specific PK 168 concentration profile of the proposed antibiotics can be mimicked. The increased prescribing of 169 alternative synergistic combinations necessitates improved in vitro methodology for evaluating 170 personalized dosing. The HFIM provides a dynamic culture solution for testing personalized antibiotic 171 regimens and exposures against the bacterial isolates cultured from the patient. This could inform 172 targeting therapy which could preserve antimicrobials and uphold antimicrobial stewardship.

173 Informed consent

The patient was consented for Orthotopic liver transplantation and normothermic perfusion as is standard for all patients and includes consent for Research publications of outcomes and the use of peri-transplant tissue samples for research. In this case no patient or deceased donor tissue was used in vitro testing.

178 **References**

- 1791.Anesi, J. A., Blumberg, E. A. & Abbo, L. M. Perioperative Antibiotic Prophylaxis to Prevent180Surgical Site Infections in Solid Organ Transplantation. *Transplantation* **102**, 21–34 (2018).
- 1812.Abbo, L. M. & Grossi, P. A. Surgical site infections: Guidelines from the American Society182of Transplantation Infectious Diseases Community of Practice. Clin Transplant **33**, (2019).
- 1833.Campos-Varela, I. et al. What is the optimal antimicrobial prophylaxis to prevent184postoperative infectious complications after liver transplantation? A systematic review of185the literature and expert panel recommendations. Clin Transplant **36**, e14631 (2022).
- 1864.Willems, R. P. J. *et al.* Incidence of infection with multidrug-resistant Gram-negative187bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-188regression analysis. Lancet Infect Dis 23, 719–731 (2023).
- 189 5. Gajic, I. *et al.* Antimicrobial Susceptibility Testing: A Comprehensive Review of Currently
 190 Used Methods. *Antibiotics* **11**, (2022).
- 1916.Sadouki, Z. et al. Application of the hollow fibre infection model (HFIM) in antimicrobial192development: a systematic review and recommendations of reporting.193doi:10.1093/jac/dkab160.
- 1947.IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections:195Version 1.0. https://www.idsociety.org/practice-guideline/amr-guidance/.
- Falcone, M. *et al.* Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With
 Bloodstream Infections Caused by Metallo-β-lactamase–Producing Enterobacterales.
 Clinical Infectious Diseases 72, 1871–1878 (2021).

- Yasmin, M. *et al.* Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the
 Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp.
 Carrying Both Klebsiella pneumoniae Carbapenemase–4 and New Delhi Metallo-β Lactamase–1. *Clin Infect Dis* **71**, 1095 (2020).
- 203 10. Falcone, M. *et al.* Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With
 204 Bloodstream Infections Caused by Metallo-β-lactamase–Producing Enterobacterales.
 205 *Clinical Infectious Diseases* **72**, 1871–1878 (2021).
- 20611.CLSI. M100 | Performance Standards for Antimicrobial Susceptibility Testing, 33rd Edition.207(2023).
- 208 12. HF-App. https://varacli.shinyapps.io/hollow_fiber_app/.
- 20913.Lutgring, J. D. *et al.* Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected210in the United States in 2017 and 2018. Antimicrob Agents Chemother 64, (2020).
- 211 14. Chauzy, A. *et al.* Pharmacodynamic modelling of β-lactam/β-lactamase inhibitor
 212 checkerboard data: illustration with aztreonam-avibactam. *Clinical Microbiology and* 213 *Infection* 25, 515–516 (2019).
- 21415.Rawson, T. M. *et al.* A practical laboratory method to determine ceftazidime-avibactam-215aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)-producing216Enterobacterales infection. J Glob Antimicrob Resist 29, 558–562 (2022).
- 217 16. Sreenivasan, P. *et al.* In-vitro susceptibility testing methods for the combination of
 218 ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms:
 219 Role of combination drugs in antibiotic resistance era. *The Journal of Antibiotics 2022 75:8*220 **75**, 454–462 (2022).
- 17. Khan, A. *et al.* Evaluation of susceptibility testing methods for aztreonam and ceftazidime avibactam combination therapy on extensively drug-resistant gram-negative organisms.
 Antimicrob Agents Chemother 65, (2021).
- 224
- 225



Figure 1. XDR *E. coli* against Ceftazidime/Avibactam/Aztreonam combination regimen in HFIM. Total bacterial population counts in CFU/mL over time. Data points for XDR *E. coli* (red) represent the geometric mean ±SD of biological duplicates. Antibiotic infusions were dosed every 8 hours (shown in black at the top of the graph). The lower LOD for quantifying the bacteria was 10 CFU/mL, shown as black dashed line.